Redeye: Xvivo Perfusion - Moving the needle
Sales came in higher than we expected in Q3 and also beat the street expectation. We forecast sales of SEK 66.8 million and EBITDA of SEK 14.1 million Q4’19.
Read more and download the research update: http://bit.ly/2Nayvm7
Start following companies at Redeye to receive the latest equity research within Life Science and Technology.
This is a press release from Redeye - Research Powered Investment Banking. https://www.redeye.se/about/